DMT category 1 clinical trials

A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

This study looks at how a blood test called serum neurofilament (sNfL) can help doctors manage multiple sclerosis (MS). It follows people with MS in Germany who are routinely tested and either continue their current treatment or switch to a new one called ofatumumab.